Small Diagnostic Chains

Dr. Lal Pathlabs Ltd.

LALPATHLAB

Market Cap
₹29,071 Cr.
P/E
57.59

Dr. Lal Pathlabs Ltd.

  • Dr. Lal Pathlabs
  • Vijaya Diagnostic
  • Metropolis Health.
  • TJI Diagnostic Chains

FAQs on Dr. Lal Pathlabs Ltd. Shareprice

Dr. Lal Pathlabs has given lower returns compared to its competitors.
Dr. Lal Pathlabs has grown at ~12.98% over the last 4yrs while peers have grown at a median rate of 25.64%

Dr. Lal Pathlabs is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Dr. Lal Pathlabs is 57.59, while 3 year average PE is 61.73.
Also latest EV/EBITDA of Dr. Lal Pathlabs is 35.99 while 3yr average is 35.81.

View FAQ's On Business

Growth Table

  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Balance Sheet

  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Cash Flow

  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Quarterly Results

  • Dr. Lal Pathlabs Ltd.
  • Vijaya Diagnostic
  • Metropolis Health.

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Dr. Lal Pathlabs Ltd. Financials

Balance sheet of Dr. Lal Pathlabs is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Dr. Lal Pathlabs is decreasing.
Latest net debt of Dr. Lal Pathlabs is -₹1,816.25 Crs as of Mar-26.
This is less than Mar-25 when it was -₹1,674.78 Crs.

Yes, profit is increasing.
The profit of Dr. Lal Pathlabs is ₹505 Crs for Mar 2026, ₹487 Crs for Mar 2025 and ₹358 Crs for Mar 2024

The company seems to pay a good stable dividend.
Dr. Lal Pathlabs latest dividend payout ratio is 68.05% and 3yr average dividend payout ratio is 55.08%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech